

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 January 2025 (09.01.2025)



(10) International Publication Number
WO 2025/008371 A1

(51) International Patent Classification:
A61K 31/538 (2006.01) *A61P 27/16* (2006.01)

(21) International Application Number:
PCT/EP2024/068658

(22) International Filing Date:
03 July 2024 (03.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23306122.5 03 July 2023 (03.07.2023) EP

(71) Applicants: **SENSORION** [FR/FR]; 375 rue du Professeur Joseph Blayac, 34080 Montpellier (FR). **COCHLEAR LIMITED** [AU/AU]; 1 University Avenue, Macquarie University, New South Wales, 2109 (AU).

(72) Inventors: **HONNET, Géraldine**; c/o SENSORION, 375 rue du Professeur Joseph Blayac, 34080 Montpellier (FR). **LEMOINE, Margaux**; c/o SENSORION, 375 rue du Professeur Joseph Blayac, 34080 Montpellier (FR). **DELGA-DO BETANCOURT, Viviana**; c/o SENSORION, 375 rue du Professeur Joseph Blayac, 34080 Montpellier (FR). **GAY, Robert Daniel**; c/o COCHLEAR LIMITED, 1 University Avenue, Macquarie University, New South Wales, 2109 (AU). **PLANT, Kerrie**; c/o COCHLEAR LIMITED, 1 University Avenue, Macquarie University, New South Wales, 2109 (AU). **SMYTH, Daniel**; c/o COCHLEAR LIMITED, 1 University Avenue, Macquarie University, New South Wales, 2109 (AU). **DUECK, Wolfram Frederick**; c/o COCHLEAR LIMITED, 1 University Avenue, Macquarie University, New South Wales, 2109 (AU). **GOLDMAN, Denise Rachael**; c/o COCHLEAR LIMITED, 1 University Avenue, Macquarie University, New South Wales, 2109 (AU).

(74) Agent: **ICOSA**; 83 avenue Denfert-Rochereau, 75014 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: AZASETRON FOR THE PRESERVATION OF RESIDUAL HEARING FOLLOWING COCHLEAR IMPLANTATION

(57) Abstract: The present invention relates to azasetron or an analog of azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for use in the preservation of residual hearing following cochlear implantation in a subject in need thereof, wherein the subject has a hearing threshold at baseline in at least one ear corresponding to an unaided audiometric threshold at baseline greater than 65 dB, the unaided audiometric threshold being expressed as the average of at least 3 values each determined at a different frequency within the range from 0.25 kHz to 0.75 kHz.

WO 2025/008371 A1